Sygnomics is developing a precision oncology platform leveraging systems biology to personalize cancer treatment plans. By analyzing individual patient data, the platform aims to provide oncologists with insights to improve patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current oncology practices often rely on limited mutation-based genomic testing, failing to fully utilize gene expression data to accurately predict disease progression and select appropriate therapies. This can lead to suboptimal treatment plans and negatively impact patient outcomes.
Solution
Sygnomics is developing a precision oncology platform that leverages systems biology and machine learning to provide individualized risk assessment and therapy matching for cancer patients. The platform, powered by SYstems Genetic Network AnaLysis (SYGNAL) technology, analyzes multi-omics data to delineate how mutations alter transcriptional programs governing disease phenotypes. By creating patient-specific disease network maps, Sygnomics can determine if a mutation is a bystander or driver and identify actionable therapeutic strategies independent of mutations, based on gene expression and network activity. The platform aims to improve patient outcomes by enabling dynamic calibration of personalized treatment plans based on the unique disease trajectory of each patient.
Target Audience
The primary target audience includes oncologists, clinical researchers, and biopharmaceutical companies seeking to improve patient outcomes through personalized precision oncology.
Features
- SYGNAL technology uses statistical inference and machine learning to mine multiomics cancer datasets
- Patient-Specific Disease-Network Map uncovers disease-perturbed network map within an individual patient by leveraging the SYGNAL model constructed from a patient cohort
- Clinical Decision Support System (CDSS) provides functionality for oncologists to browse internally vetted and shortlisted systems biology-based insights for an individual patient
- Clinical Insights Workbench (CIW) supports diverse drug discovery efforts, including novel target identification, biomarker-enriched trials, and model-based repurposing of existing FDA-approved drugs
- Prognostic tool for dynamic risk assessment to assess the severity of cancer progression at varied stages
- Therapy matching strategy to prioritize therapies that are likely to be effective for an individual patient